<DOC>
	<DOCNO>NCT01143298</DOCNO>
	<brief_summary>The purpose phase 1 study determine relative bioavailability follow single oral dose administration LEO 27847 solution compare LEO 27847 tablet healthy male subject well determine effect food single oral dose pharmacokinetics LEO 27847 tablet healthy male subject .</brief_summary>
	<brief_title>LEO 27847 - Single Dose Bioavailability Study Oral Solution Versus Tablet Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Subjects give write informed consent participate study abide study restriction . Subjects Caucasian male 18 45 year age , body mass index ( BMI ) 18 32 kg/m2 inclusive . Subjects minimum weight 50 kg Subjects must good health , determine medical history , physical examination , 12lead electrocardiogram ( ECG ) clinical laboratory evaluation ( congenital non haemolytic hyperbilirubinaemia acceptable ) male subject willing use appropriate contraception ( condom ) female partner ; occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/suppository ) time first dose 3 month final dosing occasion . Subjects receive prescribed systemic topical medication within 7 day first dose administration unless opinion Investigator medication interfere study procedure compromise safety Subjects use nonprescribed systemic topical medication ( include herbal remedy ) within 7 day first dose administration unless opinion Investigator medication interfere study procedure compromise safety Subjects receive medication , include St John 's Wort , know chronically alter drug absorption elimination process within 30 day first dose administration unless opinion Investigator medication interfere study procedure compromise safety Subjects still participate clinical study ( e.g . attend followup visit ) participate clinical study involve administration investigational drug ( new chemical entity ) , market drug within past 3 month prior first dose occasion . Subjects donate blood , plasma platelet month prior screen make donation two occasion within 12 month precede first dose administration Subjects significant history drug allergy determine Investigator Subjects clinically significant allergic disease ( exclude nonactive hay fever ) determine Investigator Subjects supine blood pressure supine pulse rate screen high 140/90 mmHg 100 beat per minute ( bpm ) , respectively , low 90/50 mmHg 45 bpm , respectively , confirm repeat Subjects consume 28 unit alcohol per week significant history alcoholism drug/chemical abuse determine Investigator Subjects smoke , smoke within 3 month prior first dose administration Subjects , history , clinically significant neurological , gastrointestinal , renal , hepatic , cardiovascular , psychiatric , respiratory , metabolic , endocrine , haematological , dermatological major disorder determine Investigator Subjects clinically significant illness within 4 week start dose administration determine Investigator Subjects know hepatitis , carrier hepatitis B surface antigen ( HBsAg ) hepatitis C antibody , positive result test HIV Subjects , opinion General Practitioner ( GP ) Investigator , participate study , include subject suspect whatever reason able comply requirement protocol</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>